NeuroSense Therapeutics Ltd.
NRSNWDrugs in Pipeline
3
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Sep 29, 2026
8wMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
Cerebrolysin
Cadasil
PrimeC
Amyotrophic Lateral Sclerosis
Cerebrolysin + donepezil
Alzheimer Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Cerebrolysin | Phase 3 | Cadasil | - | - |
PrimeC | Phase 2 | Amyotrophic Lateral Sclerosis | - | - |
Cerebrolysin + donepezil | Phase 2 | Alzheimer Disease | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in NeuroSense Therapeutics Ltd.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in NeuroSense Therapeutics Ltd.'s (NRSNW) pipeline across Phase 3, Phase 2. Its lead program is Cerebrolysin (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is NeuroSense Therapeutics Ltd.'s next FDA catalyst?→
NeuroSense Therapeutics Ltd.'s (NRSNW) next tracked catalyst is a Regulatory expected September 29, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track NRSNW biotech catalysts?→
Add NRSNW to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow NeuroSense Therapeutics Ltd.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.